Mentions
Extended reach
Total likes
Video views
AI synopsis
Across the social discussions, participants express strong agreement with the study’s positive outcomes, calling it a 'landmark article' and highlighting its potential to change practice—words like 'AMAZING' and 'game changer' convey excitement. Detailed references to the trial design, results, and comparisons to earlier studies demonstrate deep engagement and recognition of the research's high impact on ongoing cardiovascular and renal care.
Most discussions strongly support the positive findings of the study, emphasizing its significance for heart failure treatment.
The posts show high interest, with many referencing the study as groundbreaking and mentioning its implications for clinical practice.
Several posts analyze the methods, emphasize the study's relevance, and compare it with previous research, indicating deep engagement.
The discussions reflect that this research could significantly influence treatment guidelines and clinical decision-making, indicating high impact.
LANDMARK ARTICLE: SGLT2 drugs for CHF even without diabetes. Just so AMAZING!!! Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure https://t.co/TpYQE2PyJc
2020: EMPEROR-Reduced Empagliflozin tested in pts with heart failure and ejection fraction ≤ 40%, regardless of diabetes. Result: decreased hospitalization for HF, decreased CV death. https://t.co/Mh7ljQ9EDm 13/20
EMPEROR-REDUCED
Medicina Interna Lunes 14 de septiembre: 7:00 am Tema: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR) Presenta: Dra. Ángela María López [https://t.co/BnW3XW4jdH]
This video discusses the recent findings on lingering inflammation in athletes' hearts following COVID-19, particularly noting a study highlighting that 15% of college athletes show this issue. The study emphasizes the…
Learn about the optimal medication prescriptions for patients with HFrEF based on the 2021 ESC Guidelines. This video discusses vericiguat, a promising new medication shown to reduce cardiovascular events in high-risk…
Professor Stefan Anker presents key findings from the EMPEROR Preserved study, the first major randomized trial demonstrating a prognostic benefit of pharmacotherapy for patients with heart failure and preserved…
This video explores the optimal medication strategies for patients with heart failure and reduced ejection fraction, in accordance with the 2021 ESC Guidelines. It examines the efficacy of new treatments, including…
RT @SeeFisch: LANDMARK ARTICLE: SGLT2 drugs for CHF even without diabetes. Just so AMAZING!!! Cardiovascular and Renal Outcomes with Empag…
RT @SeeFisch: LANDMARK ARTICLE: SGLT2 drugs for CHF even without diabetes. Just so AMAZING!!! Cardiovascular and Renal Outcomes with Empag…
RT @SeeFisch: LANDMARK ARTICLE: SGLT2 drugs for CHF even without diabetes. Just so AMAZING!!! Cardiovascular and Renal Outcomes with Empag…
RT @richykirsh: @MichaelAndre81 @Hornblower1941 @Boris4T @VaxPaparazzi @ShaneAKAProp @market_memetics @NexusSwords @AlBowers1 @Agent2Dark @…
@MichaelAndre81 @Hornblower1941 @Boris4T @VaxPaparazzi @ShaneAKAProp @market_memetics @NexusSwords @AlBowers1 @Agent2Dark @TannersHouseM8 @timefears88 @saltbeefsandwch @villagerssn @lavalmxhr @crabb_vicki @Pouldeau61 @desktopcarl @BurgerLab12 @Jacqueline_pray @zee_parody @KinseyKat1 @Mike6150817700 @YourFerntasy @karleastlondon1 @STAR7ZEN @suburbiadeepsix @JimeeLiberty @returns8143 @FredEast11 @jilel76 @AnnLove4All @ghostwhite916 @GhostOfChaplin @Alex_on_A14 @Scary7Dr @J91U17 @RopeyLabs @spursonfifa @myshinyfriend @sduncanhealth @2025norefunds @ForeverAutumn68 @Mike700110111 @NeverVexed @michaelHoe89274 @mcfunny @TruthHurts02160 @dale47844467 @dirk_fasshauer @TheHammerT800 What ever happened to his cardiorenal society? I know, Milt Packer happened. https://t.co/FE7a4GAGVv
@kaulcsmc @drjohnm @adamcifu @VPrasadMDMPH Thank you for your reply! So for example, you would agree that 1. HFH, and 2. eGFR Both considered definitive in EMPEROR-Reduced https://t.co/RuFVA9FJ1p
2020: EMPEROR-Reduced Empagliflozin tested in pts with heart failure and ejection fraction ≤ 40%, regardless of diabetes. Result: decreased hospitalization for HF, decreased CV death. https://t.co/Mh7ljQacsU
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/RYyv937zvK
@DocChukx @RyanTedfordMD @SJGreene_md @hvanspall @mvaduganathan @heartsuccessPA @ajaysmd @AndrewJSauer @JonathanDavisHF @JJheart_doc @Carnicelli_Ant Yes EMPEROR-Reduced RCT Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/WmM98W8fgB
RT @nobbie_jr: @damilola_MD “Primary outcome event occurred in 361 of 1863 patients (19.4%) in the SGLT2 group and in 462 of 1867 patients…
@damilola_MD “Primary outcome event occurred in 361 of 1863 patients (19.4%) in the SGLT2 group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for CVD or hospitalization for heart failure, 0.75; 95% [CI], 0.65 to 0.86; P<0.001).” https://t.co/YiKrwrh30R
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (2017) "...those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes." https://t.co/xqKoHtIEbJ
Original Article: https://t.co/mb9hVqTkdz
RT @SeeFisch: LANDMARK ARTICLE: SGLT2 drugs for CHF even without diabetes. Just so AMAZING!!! Cardiovascular and Renal Outcomes with Empag…
RT @SeeFisch: LANDMARK ARTICLE: SGLT2 drugs for CHF even without diabetes. Just so AMAZING!!! Cardiovascular and Renal Outcomes with Empag…
RT @SeeFisch: LANDMARK ARTICLE: SGLT2 drugs for CHF even without diabetes. Just so AMAZING!!! Cardiovascular and Renal Outcomes with Empag…
RT @SeeFisch: LANDMARK ARTICLE: SGLT2 drugs for CHF even without diabetes. Just so AMAZING!!! Cardiovascular and Renal Outcomes with Empag…
RT @SeeFisch: LANDMARK ARTICLE: SGLT2 drugs for CHF even without diabetes. Just so AMAZING!!! Cardiovascular and Renal Outcomes with Empag…
RT @SeeFisch: LANDMARK ARTICLE: SGLT2 drugs for CHF even without diabetes. Just so AMAZING!!! Cardiovascular and Renal Outcomes with Empag…
RT @SeeFisch: LANDMARK ARTICLE: SGLT2 drugs for CHF even without diabetes. Just so AMAZING!!! Cardiovascular and Renal Outcomes with Empag…
RT @SeeFisch: LANDMARK ARTICLE: SGLT2 drugs for CHF even without diabetes. Just so AMAZING!!! Cardiovascular and Renal Outcomes with Empag…
RT @SeeFisch: LANDMARK ARTICLE: SGLT2 drugs for CHF even without diabetes. Just so AMAZING!!! Cardiovascular and Renal Outcomes with Empag…
LANDMARK ARTICLE: SGLT2 drugs for CHF even without diabetes. Just so AMAZING!!! Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure https://t.co/TpYQE2PyJc
RT @AkivaRosenzveig: 2/19 RCTs in the '80s and '90s used mortality as a PEP But with more effective therapies, mortality has decreased! e…
RT @AkivaRosenzveig: 2/19 RCTs in the '80s and '90s used mortality as a PEP But with more effective therapies, mortality has decreased! e…
2/19 RCTs in the '80s and '90s used mortality as a PEP But with more effective therapies, mortality has decreased! e.g. SOLVD ('91) showed mortality in Rx arm of 35.2% vs mortality in Rx arm of EMPEROR-Reduced (2020) was 10%
...the combined risk of CV death or hospitalization for HF was 25% lower among the patients who received empagliflozin than among those who received placebo, a difference that was primarily related to a 31% lower risk of hospitalization for heart failure. https://t.co/7I9zrfL1sf
EMPEROR-Reduced (https://t.co/9bcvrExJyE) demonstrated a reduction in the primary outcome of #cardiovascular death or hospitalization for worsening #heart failure in pts with EF < or = 40%, irrespective of #diabetes status
RT @AMAREVA_Madrid:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @AMAREVA_Madrid:
RT @AMAREVA_Madrid:
RT @AMAREVA_Madrid:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
RT @Diabetes_SEMI:
2020: EMPEROR-Reduced Empagliflozin tested in pts with heart failure and ejection fraction ≤ 40%, regardless of diabetes. Result: decreased hospitalization for HF, decreased CV death. https://t.co/Mh7ljQ9EDm 13/20
3) EMPEROR-Reduced trial
RT @ckd_ce: 16) #Empagliflozin Outcome Trials in Patients w/ Chronic HF (EMPEROR) provided clear evidence of efficacy & safety for empa in…
16) #Empagliflozin Outcome Trials in Patients w/ Chronic HF (EMPEROR) provided clear evidence of efficacy & safety for empa in patients w/ #eGFR >/= 20 & HF #VisualAbstract by @whatsthegfr #EMPEROR_Preserved
RT @BertrandBio: @Mykalt45 @SamFazeli8 CV death were reduced by 9% (HR 0.91) in HF with preserved Ejection Fraction in EMPEROR-Preserved &…
@Mykalt45 @SamFazeli8 CV death were reduced by 9% (HR 0.91) in HF with preserved Ejection Fraction in EMPEROR-Preserved & by 8% (HR 0.92) in EMPEROR-Reduced https://t.co/WeNVA44oOT https://t.co/gmrDyiHRFk
Link: https://t.co/66sfw2aeM4
28) A subsequent #HF trial with the #SGLT2i #Empagliflozin also met its primary endpoint:
RT @accpcardprn: EMPEROR-REDUCED
EMPEROR-REDUCED
ジャディアンス主要試験 【EMPEROR-Reduced試験】 2型糖尿病合併の有無に関わらず、左室駆出率が低下していて（LVEF≦40%）、NYHA2～4度の状態にあるHFrEF患者に対して、プラセボと比較して、心血管死亡または心不全入院は25%有意に低下した（95%CI：0.65-0.86、P＜0.001）。 https://t.co/d78hGcLoYr
Packer et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. @NEJM 2020. View the summary here: https://t.co/FlskLiTD2v
EMPEROR-Reduced Trial https://t.co/65g2XHykts
https://t.co/65g2XHykts
RT @SPSWRPhaclub: استضاف نادي صيادلة المنطقة الغربية ضمن فئة نوادي المجلات فعاليته الأولى في يوم الثلاثاء الموافق ٩ نوڤمبر٢٠٢١م ،الساعة ٧ م…
RT @SPSWRPhaclub: استضاف نادي صيادلة المنطقة الغربية ضمن فئة نوادي المجلات فعاليته الأولى في يوم الثلاثاء الموافق ٩ نوڤمبر٢٠٢١م ،الساعة ٧ م…
RT @SPSWRPhaclub: استضاف نادي صيادلة المنطقة الغربية ضمن فئة نوادي المجلات فعاليته الأولى في يوم الثلاثاء الموافق ٩ نوڤمبر٢٠٢١م ،الساعة ٧ م…
RT @SPSWRPhaclub: استضاف نادي صيادلة المنطقة الغربية ضمن فئة نوادي المجلات فعاليته الأولى في يوم الثلاثاء الموافق ٩ نوڤمبر٢٠٢١م ،الساعة ٧ م…
RT @SPSWRPhaclub: استضاف نادي صيادلة المنطقة الغربية ضمن فئة نوادي المجلات فعاليته الأولى في يوم الثلاثاء الموافق ٩ نوڤمبر٢٠٢١م ،الساعة ٧ م…
استضاف نادي صيادلة المنطقة الغربية ضمن فئة نوادي المجلات فعاليته الأولى في يوم الثلاثاء الموافق ٩ نوڤمبر٢٠٢١م ،الساعة ٧ مساءً بعنوان Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure للصيدلانية المقيمة د. عائشة الحربي، من مستشفى جامعة الملك عبدالعزيز..يتبع
Empagliflozin: In patients with type 2 diabetes, Empagliflozin (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and the risk of serious adverse renal events, benefits that are not seen with other antihyperglycemic drugs https://t.co/pIcL0l5xUp.
RT @SIAC_cardio: EMPEROR REDUCED 3730 pac HFrEF fey<40% CFII-IV 16 meses FU Punto final 1:
は〜！ Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/bshPA5GYEh
RT @cardiomet_CE: 2) EMPEROR-Pooled was a prespecified analysis of the two 'sister' studies EMPEROR-Reduced Trial https://t.co/c5DVyV1TDj…
RT @cardiomet_CE: 2) EMPEROR-Pooled was a prespecified analysis of the two 'sister' studies EMPEROR-Reduced Trial https://t.co/c5DVyV1TDj…
RT @cardiomet_CE: 2) EMPEROR-Pooled was a prespecified analysis of the two 'sister' studies EMPEROR-Reduced Trial https://t.co/c5DVyV1TDj…
RT @cardiomet_CE: 2) EMPEROR-Pooled was a prespecified analysis of the two 'sister' studies EMPEROR-Reduced Trial https://t.co/c5DVyV1TDj…
RT @cardiomet_CE: 2) EMPEROR-Pooled was a prespecified analysis of the two 'sister' studies EMPEROR-Reduced Trial https://t.co/c5DVyV1TDj…
RT @cardiomet_CE: 2) EMPEROR-Pooled was a prespecified analysis of the two 'sister' studies EMPEROR-Reduced Trial https://t.co/c5DVyV1TDj…
2) EMPEROR-Pooled was a prespecified analysis of the two 'sister' studies EMPEROR-Reduced Trial https://t.co/c5DVyV1TDj and EMPEROR-Preserved Trial https://t.co/OckYa64i4P With very similar #HeartFailure populations, separated by an ejection fraction cut off of 40% https://t.co/sLTWgxJqzg
#022 Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure N Engl J Med 2020;383:1413-24.
@hmkyale @escardio Still adds new insight since LVEF 40-50% was not included in EMPEROR HF, just not sure LVEF 55%+ would still be significant https://t.co/FGPUDz5ILR
دراسة (EMPEROR-reduced): دواء (#Jardiance) ⬇️ نسبة الوفاة من أمراض القلب ودخول المستشفى لدى مرضى الفشل القلبي ذوو الكسر الطردي <٤٠٪ (HFpEF)
NEJM - Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure - https://t.co/OIqLn4Yzwu
La nueva indicación en insuficiencia cardiaca no se encuentra actualmente financiada en España. Packer M et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.2.https://t.co/n1qP8XSZ9U
RT @redGDPS: Estudio #EMPEROR_REDUCE con @anicebrian https://t.co/Y5y6973zou https://t.co/wX1x8yCSoX #avanzadoredGDPS https://t.co/UnbhW3…
RT @redGDPS: Estudio #EMPEROR_REDUCE con @anicebrian https://t.co/Y5y6973zou https://t.co/wX1x8yCSoX #avanzadoredGDPS https://t.co/UnbhW3…
RT @redGDPS: Estudio #EMPEROR_REDUCE con @anicebrian https://t.co/Y5y6973zou https://t.co/wX1x8yCSoX #avanzadoredGDPS https://t.co/UnbhW3…
RT @redGDPS: Estudio #EMPEROR_REDUCE con @anicebrian https://t.co/Y5y6973zou https://t.co/wX1x8yCSoX #avanzadoredGDPS https://t.co/UnbhW3…
RT @redGDPS: Estudio #EMPEROR_REDUCE con @anicebrian https://t.co/Y5y6973zou https://t.co/wX1x8yCSoX #avanzadoredGDPS https://t.co/UnbhW3…
RT @redGDPS: Estudio #EMPEROR_REDUCE con @anicebrian https://t.co/Y5y6973zou https://t.co/wX1x8yCSoX #avanzadoredGDPS https://t.co/UnbhW3…
Estudio #EMPEROR_REDUCE con @anicebrian https://t.co/Y5y6973zou https://t.co/wX1x8yCSoX #avanzadoredGDPS https://t.co/UnbhW3hCDR
@KateIsabelle24 @askrenal https://t.co/jKySESM2ln Same rationale but for the increasing population of patients with CKD and HF independent of DKD and proteinuria
RT @KardiologieHH: 2/ EMPEROR-Reduced Studie präsentiert von Prof. Stefan D. Anker (@ChariteBerlin; Berlin) Cardiovascular and Renal Outco…
2/ EMPEROR-Reduced Studie präsentiert von Prof. Stefan D. Anker (@ChariteBerlin; Berlin) Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (@NEJM by @FaiezZANNAD ) Link: https://t.co/TyCR6ylgw7 https://t.co/mBnLKkmdpl
RT @q0_0_: EMPEROR-Reduced trial, NEJM 2020 心不全患者に対するempaglifrozin 10mg (vs. placebo)の心不全予防効果を評価したランダム化二重盲検比較試験(3730人)において、心不全入院率の低下のみならず、e…
EMPEROR-Reduced trial, NEJM 2020 心不全患者に対するempaglifrozin 10mg (vs. placebo)の心不全予防効果を評価したランダム化二重盲検比較試験(3730人)において、心不全入院率の低下のみならず、eGFR低下の抑制効果が確認された。心不全死の抑制効果は確認されていない。 https://t.co/1xBClv3cyJ https://t.co/4grOA73jll
RT @GarciaQuintanaA: I ❤️ it when a plan comes together. EMPEROR
EMPEROR-Reduced: Among HF patients regardless of diabetes status, empagliflozin in addition to recommended HF therapy was associated with lower CV death and hospitalizations for HHF compared to placebo #UMKCRCT https://t.co/ZTNyCVJZtO
Will this change your practice? #Empagliflozin #HeartFailure https://t.co/Frdzvpk2Ib
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
#ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further reading: https://t.co/gZYEfZthJV https://t.co/pxg7VuTPmM https://t.co/TkL1bUZAzh https://t.co/jiReouHd2o https://t.co/afT6tGHSqa https://t.co/0aWpT6gJc6 https://t.co/KSEVGqkcZD
@LaraAHayes @EvidenceBasedMD @SuchitaSata @sjenkinsmd @jvk213 @AmberLBowman96 @AimeeZaas @danibabbel Maybe I’m the only one still amazed by this, but I love the SGLT2 effects in heart failure. 1 drug with multiple positive effects? Awesome!! https://t.co/Q9NvGB31rG
https://t.co/wh4XIfkWyE https://t.co/D8Rf4o3Rze
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/0zTRFPqdAB Proof of principle: Empagliflozin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: 14/February/2018, 10.54 pm https://t.co/AcNii6eQg5
RT @gcfmd: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/Ah3jji7kBK
RT @JuliaSellerm:
RT @JuliaSellerm:
RT @JuliaSellerm:
RT @ssfarouk:
RT @hvanspall: 20 min masterclass on the history of #SGLT2i RCTs, key diffs between #EMPEROR_REDUCED & #DAPAHF, how risk profile of patient…
RT @hvanspall: 20 min masterclass on the history of #SGLT2i RCTs, key diffs between #EMPEROR_REDUCED & #DAPAHF, how risk profile of patient…
心不全に対するエンパグリフロジン 非糖尿病患者における低血糖の発現が1％未満で、プラセボと変わらないの不思議。 https://t.co/hhKggn0X82
#EMPEROR_Reduced N Engl J Med 2020; 383:1413-1424 DOI: 10.1056/NEJMoa2022190
Nutshell #141: Combined risk of cardiovascular death or hospitalization for heart failure was lower after empagliflozin therapy in patients with advanced but stable chronic heart failure, with or without diabetes. @Baylor in @NEJM https://t.co/E71CG7oraH
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/ARA8MxRwoR
RT @edgarvlermamd: EMPEROR-REDUCED: Among patients on recommended therapy for heart failure (HF), those on empagliflozin had ⬇️ risk of CV…
RT @edgarvlermamd: EMPEROR-REDUCED: Among patients on recommended therapy for heart failure (HF), those on empagliflozin had ⬇️ risk of CV…
RT @edgarvlermamd: EMPEROR-REDUCED: Among patients on recommended therapy for heart failure (HF), those on empagliflozin had ⬇️ risk of CV…
RT @edgarvlermamd: EMPEROR-REDUCED: Among patients on recommended therapy for heart failure (HF), those on empagliflozin had ⬇️ risk of CV…
Next up https://www.nejm.org/doi/full/10.1056/NEJMoa2022190 #kidneywk2020 high impact 2020
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/Oa7Fv7QRuK
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. https://t.co/2FIODeQWgM https://t.co/YedXD6v5pA
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/yEcKv8ar2e
Étude randomisée contrôlée chez des insuffisants cardiaques avec fraction d’éjection < 40%, comparant l'empagliflozine au placebo. Le groupe empagliflozine a eu un risque < de décès cardiovasculaire ou d'hospitalisation pour insuffisance cardiaque https://t.co/eLvm8CAQH0 https://t.co/eFP0JkdKE5
A study in #cardiovascular and renal outcomes with empagliflozin in heart failure found patients in the empagliflozin group had a lower risk of death or hospitalization for #heartfailure, regardless of the presence or absence of diabetes. https://t.co/CkYUo82Ly7
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure https://t.co/BJd0MyrOYa
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure https://t.co/anwCyWzX2x
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/jYVo3siVnW
RT @SehsuvarErturk: Bugün #NEJM #SGLT2i Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure https://t.co/bFZo4MNXBb Dapa…
Bugün #NEJM #SGLT2i Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure https://t.co/bFZo4MNXBb Dapagliflozin in Patients with Chronic Kidney Disease https://t.co/VkCB2nJ9wx Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes https://t.co/gDtN4HLamr
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/lhuDOnEMDi
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/GIhqYMVm6F
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/tWMI45OI3E
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/AKY1zv8AzQ We're presenting this in Morning Report tomorrow! Results of the EMPEROR-Reduced trial.
これが話題のEMPEREORか。 これでエンパグリフロジンも晴れて心不全治療薬。 #GDMTの変遷 Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/ytjWw54NIf
RT @redGDPS: Por si quereis completar la información del estudio #EMPEROR, os dejamos el enlace al mismo #webgdps #Diabetes #IC https://t.c…
Por si quereis completar la información del estudio #EMPEROR, os dejamos el enlace al mismo #webgdps #Diabetes #IC https://t.co/3V8p0vZhAb
RT @PerlasClinicas: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure - Journal Club. Departamento de Medicina Interna…
RT @PerlasClinicas: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure - Journal Club. Departamento de Medicina Interna…
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure - Journal Club. Departamento de Medicina Interna @Medicina_UdeA [https://t.co/zZVI5VQ6Lo]. Presenta: Dra Angela López, residente de medicina interna.
Tomorrow, at Noon CT, the NPA is hosting a journal club by Zoom. Learn more about cardiovascular and renal outcomes with Empagliflozin in heart failure. Register at this link: https://t.co/W4RMwtkgMu https://t.co/rQRWyvJsl7
[
On September 23, at Noon CT, the NPA is hosting a journal club by Zoom. Learn more about cardiovascular and renal outcomes with Empagliflozin in heart failure. Register at this link: https://t.co/W4RMwtkgMu https://t.co/ZFJlH61TOJ
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/m1AW3wLsY4
Medicina Interna Lunes 14 de septiembre: 7:00 am Tema: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR) Presenta: Dra. Ángela María López [https://t.co/BnW3XW4jdH]
EvidenceAlerts | Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. https://t.co/NHCVSnk1pN
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/7rLyk9HIKl
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. https://t.co/r4OXt9HfI4
ECA: Empagliflocina (iSGLT2) vs placebo.
【RCT】駆出率40%以下のNYHA分類II-IV度の心不全患者へのエンパグリフロジン投与は、プラセボの投与と比較して、糖尿病の有無に関係なく心血管死亡や心不全による入院を減少させた。eGFRの年間減少率はエンパグリフロジン群で低下し、重篤な腎転帰リスクも減少した。 #ペ読 https://t.co/BJw9QDcCe0
Trending on PubMed: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. https://t.co/6s7Egt5QAV
EMPEROR REDUCED. New evidences in #HeartFailure Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/uxWU0aptxd
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/uAzIotQEaz
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/Arg0RGbHer
RT @SehsuvarErturk: Bugün #NEJM #SGLT2 inhibitörü empagliflozin #diyabet olsun veya olmasın #kalpyetersizliği olan hastalarda hem #kalp hem…
Bugün #NEJM #SGLT2 inhibitörü empagliflozin #diyabet olsun veya olmasın #kalpyetersizliği olan hastalarda hem #kalp hem de #böbrek ilişkili olumsuz sonuçları önlemede plaseboya üstün. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure https://t.co/Ni0xeESoSo
What a great study acronym. #EMPEROR Trial. @IanJStewart3 Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/FyWxEPFg77
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/ixvjPGsSod
糖尿病の有無にかかわらずSGLTｰ2阻害薬を使うと心不全による死亡と入院の可能性を減らすことができることがわかった模様（1つのRCT エビデンスレベル1b） Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/IG8wDkcq9B
Trend up+1: **Packer M** et al (N Engl J Med) __Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure__ https://t.co/jOQvVANTHG
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. https://t.co/z8PR9p2oDx https://t.co/vdxGhpiQ93
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM. #ESCCongress https://t.co/372KnoXvz6
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/u5WXAWUQrl "Empagliflozin group had a lower risk of cardiovascular death or hospitalization" Proof of principle/concept/validation (refer below): https://t.co/OdquFv1GmU
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/gKV2baj5Kt "Empagliflozin group had a lower risk of cardiovascular death or hospitalization" Proof of principle/concept/validation (refer below): https://t.co/OdquFv1GmU
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/2QLKWxxbuL "Empagliflozin group had a lower risk of cardiovascular death or hospitalization" Proof of principle/concept/validation (refer below): https://t.co/OdquFvjhLu
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/g87OY855ud Proof of principle/concept/validation (What we stated nearly 3 years ago-refer below): https://t.co/OdquFv1GmU
RT @NEJM: Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
RT @NEJM: Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/NHQ0zNvN2f
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/fp1OUMKL5v
RT @Sefap_FAP: (NEJM) Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure https://t.co/JBLYcRnFmT
RT @Sefap_FAP: (NEJM) Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure https://t.co/JBLYcRnFmT
#ESCCongress – [Abstract Only] Randomized trial: Cardiovascular and renal outcomes with Empagliflozin in heart failure – via @NEJM https://t.co/1WVq8Ebail Commentary: https://t.co/h71IiapwUq
(NEJM) Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure https://t.co/JBLYcRnFmT
RT @RealTNagasawa: これもすごいデータ出てきたな。 Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/1JWz7LLtUm
RT @NEJM: Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
RT @NEJM: Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
RT @redGDPS: Publicado recientemente en @NEJM , en primicia de nuestro compañero @JoanBarrot ⭕️ Cardiovascular and Renal Outcomes with…
これもすごいデータ出てきたな。 Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/1JWz7LLtUm
RT @NEJM: Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
RT @NEJM: Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
RT @NEJM: Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
#cardiovascular and #Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/S1SQqOnkvC
RT @NEJM: Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
RT @proychaudhuryMD: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://t.co/ysOvz6Y3WG
RT @NEJM: Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
RT @NEJM: Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
RT @NEJM: Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
RT @NEJM: Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
RT @NEJM: Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2022190
TS